This is a fast-moving area, so here's an honest breakdown: Context First The FDA declared the semaglutide shortage over in 2024, which triggered a crackdown on compounded versions. The situation for tirzepatide is similar. Rules are still evolving, so availability changes frequently. Services That Have Continued Offering Compounded GLP-1s (as of early 2025) Hims & Hers - fought to continue compounded semaglutide and tirzepatide; has been vocal about legal challenges Ro - offered compounded versions but adjusted based on regulatory pressure LifeMD/GoTelehealth - continued offering compounded options Mochi Health - has offered compounded semaglutide through partner pharmacies Henry Meds - has offered compounded options Important Caveats Verify current availability directly - this changes week to week Some services pivoted to personalized/combination formulas to maintain a regulatory argument for compounding FDA enforcement actions are ongoing and lawsuits are in play Quality varies significantly between compounding pharmacies My Honest Recommendation Check current status directly with each service, and ask which FDA-registered 503B compounding pharmacy they use - that's a meaningful quality indicator. Would you like more detail on any specific aspect?
Mentioned in position 4 of 6
Read full answer with sources →